Supriya Lifescience

Analysts believe the company is well-positioned for "sustained, high-quality growth," reinforcing long-term earnings visibility

Supriya Lifescience share slipped 5.65 per cent at Rs 661.20 a piece on the BSE in Monday's intraday trade despite the pharma company reporting strong quarterly earnings for the financial year 2024-25

Supriya Lifescience Chairman and Whole-Time Director Satish Wagh said he was confident of achieving 22 per cent year-on-year revenue growth in the current financial year (FY25)

Supriya Lifesciences share price surged after the company inaugurated a new active pharmaceutical ingredients (APIs) production block, Module E, at the Lote Parshuram site in Maharashtra

This ambition follows the company's recent approval from Anvisa (Brazilian health regulatory agency), which has facilitated its entry into the Brazilian market

Quickblue is designed to detect oral cancer swiftly, eliminating the need for extensive preclinical and clinical trials

Zomato ends 9% down, slips below listing price; Supriya LifeScience tanks 18% on disappointing Q3 earnings; Adani Wilmar IPO to open on Jan 27; price band fixed at Rs 218-230 apiece

Heightened selling pressure in stocks where anchor contribution is high. Five of the 12 firms had allocated more than 10% of outstanding shares to anchor investors

Supriya Lifescience has a niche product portfolio of 38 APIs with focus primarily on diverse therapeutic areas.

The initial public offering (IPO) of Supriya Lifescience was subscribed 74x

The BSE Midcap index and Smallcap indices also finished with smart gains of 1 per cent and 1.5 per cent, respectively.

The IPO had received a strong response, which was subscribed 71.51 times on back of robust subscription of individual investors

It was a choppy trading session on Monday with indices recovered sharply from their day's lows. Year-end holidays across major markets and Omicron threat capped the gains. What's in store for Tuesday?

Surpiya Lifescience is likely to make a bumper debut on the stock exchanges, with GMP indicating a likely listing gain of 40-45 per cent for the stock

Supriya Lifesciences had priced its IPO between Rs 265 and Rs 274 per share

Oil prices fall up to 5% as demand concerns weigh; Centre bans futures trade in seven agri commodities; Singapore index steals a march over NSE in Nifty futures volumes in 2021

Growth prospects and scope for margin expansion are other triggers, say brokerages

Bajaj twins can slide another 10% from current levels; Supriya Lifescience IPO fully subscribed within hours of opening